Physician profile
Lora A Crowley
NPI 1932207511
$8,021.00
in general payments reported to CMS, 2019-2025
40 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,396 · 2022: $1,373 · 2023: $1,297 · 2024: $1,797 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,953 · Consulting Fee: $200 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,952.64 |
| Consulting Fee | $200.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,187.25 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $842.60 | 2021-2025 | Wakix |
| Insmed, INC. | $718.43 | 2021-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $651.46 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $647.01 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Genzyme Corporation | $461.05 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $349.57 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Jazz Pharmaceuticals INC. | $346.65 | 2021-2024 | |
| Electromed, INC. | $342.03 | 2022-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.62 | 2021-2025 | Ofev, Spiriva Respimat, Jascayd |
| Novartis Pharmaceuticals Corporation | $253.07 | 2021-2024 | |
| Mylan Specialty L.P. | $248.56 | 2021-2024 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $244.54 | 2024-2025 | Lumryz |
| Merck Sharp & Dohme LLC | $115.75 | 2022-2023 | Belsomra |
| Verona Pharma, INC. | $109.72 | 2025 | Ohtuvayre |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Grifols USA, LLC | $88.10 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Axsome Therapeutics, INC. | $84.07 | 2023-2024 | Sunosi |
| United Therapeutics Corporation | $82.68 | 2021-2022 | |
| Advanced Respiratory, INC | $79.02 | 2021 | |
| Philips North America LLC | $76.89 | 2021-2024 | (Ak6) Vest Therapy |
| Covis Pharma Gmbh | $65.96 | 2021 | |
| Ani Pharmaceuticals, INC. | $59.41 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $56.44 | 2022-2024 | |
| Pulmonx Corporation | $54.37 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Takeda Pharmaceuticals U.S.A., INC. | $53.37 | 2021-2022 | |
| Abbvie INC. | $38.76 | 2022 | |
| Eisai INC. | $35.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.67 | 2021 | |
| Idorsia Pharmaceuticals US INC | $34.38 | 2023-2024 | Quviviq |
| Tactile Systems Technology INC | $29.52 | 2025 | Nimbl, Flexitouch Plus |
| Lilly USA, LLC | $28.42 | 2025 | Zepbound |
| Inogen, INC. | $26.00 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Alexion Pharmaceuticals, INC. | $24.79 | 2021 | |
| Sanofi Pasteur INC. | $23.84 | 2023 | |
| Csl Behring | $23.26 | 2021 | |
| Vifor Pharma, INC. | $21.14 | 2025 | Zemaira |
| Resmed Corp | $20.37 | 2024 | |
| Vapotherm INC | $18.46 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Crowley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.